Janelle Bradley

News
Real-World Experience With Bevacizumab for Newly Diagnosed Ovarian Cancer
03/22/2022
Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.
Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.
Among patients with ovarian...
03/22/2022
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
Conference Coverage
Second-Line Use of CDK4/6 Inhibitors Plus Endocrine Therapy Superior to First-Line Use in Advanced Breast Cancer
06/05/2023
First-line use of CDK4/6 inhibition plus endocrine therapy does not provide PFS benefit vs second-line use in patients with HR-positive, HER2-negative advanced breast cancer, according to results from the phase 3 SONIA trial.
First-line use of CDK4/6 inhibition plus endocrine therapy does not provide PFS benefit vs second-line use in patients with HR-positive, HER2-negative advanced breast cancer, according to results from the phase 3 SONIA trial.
First-line use of CDK4/6...
06/05/2023
Oncology
Conference Coverage
First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting
12/11/2021
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use...
12/11/2021
Journal of Clinical Pathways
News
Adebrelimab Plus Chemotherapy Improves Survival Among Patients With Extensive-Stage SCLC
05/19/2022
Findings from the phase 3 CAPSTONE-1 trial show the addition of adebrelimab to chemotherapy for the first-line treatment of patients with extensive-stage SCLC significantly improves survival.
Findings from the phase 3 CAPSTONE-1 trial show the addition of adebrelimab to chemotherapy for the first-line treatment of patients with extensive-stage SCLC significantly improves survival.
Findings from the phase 3...
05/19/2022
Oncology
NCCN Updates Clinical Practice Guideline for NSCLC
NCCN Updates Clinical Practice Guideline for NSCLC
03/03/2021
The National Comprehensive Cancer Network released an update to its guideline for non-small cell lung cancer.
The National Comprehensive Cancer Network released an update to its guideline for non-small cell lung cancer.
The National Comprehensive...
03/03/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim for Patients at Risk for Febrile Neutropenia
02/21/2022
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary...
02/21/2022
Journal of Clinical Pathways
Conference Coverage
Camrelizumab Plus Apatinib Demonstrates Promising Antitumor Activity, Manageable Safety in Endometrial Cancer
06/09/2022
In a phase 2 trial, camrelizumab plus apatinib demonstrated promising antitumor activity and manageable safety in patients with advanced or recurrent endometrial cancer that did not respond to first-line therapy.
In a phase 2 trial, camrelizumab plus apatinib demonstrated promising antitumor activity and manageable safety in patients with advanced or recurrent endometrial cancer that did not respond to first-line therapy.
In a phase 2 trial, camrelizumab...
06/09/2022
Oncology
Conference Coverage
Second-Line Polatuzumab Vedotin Plus RICE Yields High Response Rates in Relapsed/Refractory DLBCL
12/11/2022
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) yields encouraging responses in patients with relapsed/refractory DLBCL, according to a phase 2 study.
Second-line treatment with...
12/11/2022
Oncology
News
Factors Associated With Exceeding Target Price Under OCM for Episodes of Breast Cancer
03/21/2022
Study findings show breast cancer episodes in older women with distant metastases frequently exceeded the target price under the OCM payment methodology.
Study findings show breast cancer episodes in older women with distant metastases frequently exceeded the target price under the OCM payment methodology.
Study findings show breast...
03/21/2022
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use